City of Hope Diabetes Experts Presented Innovative Research at Annual American Diabetes Association (ADA) Conference
MIAMI, FL, June 24, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
Results from the CATALYST clinical trial were presented at the American Diabetes Association’s 84th Scientific Sessions at a featured plenary session titled: “Prevalence of Hypercortisolism in...
MIAMI, FL / ACCESSWIRE / June 24, 2024 / iTolerance Inc. announced today that the Diabetes Research Institute (DRI) at the University of Miami Miller School of Medicine was thrilled to unveil groundbreaking results presented at the American Diabetes Association's (ADA) 84th Scientific Sessions. This innovative approach highlights the potential of human stem cell-derived islets combined with an immunomodulatory microgel to reverse Type 1 Diabetes (T1D). This technology was developed to enable pancreatic islet cells replacement in the allogeneic setting (from a donor to an unrelated recipient) without the need for chronic systemic immunosuppression.
BEIJING and BRIDGEWATER, N.J., June 22, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced the results of the Phase 1b/2a clinical study of the Company's independently developed glucagon-like peptide-1 (GLP-1) receptor agonist, GZR18 Injection, in an obese/overweight population in China, along with the results of two other innovative insulins' preclinical studies in poster presentations at the American Diabetes Association's?ADA's?84th Scientific Sessions.
ORLANDO, Fla., June 22, 2024 /PRNewswire/ -- Today, the American Diabetes Association ® (ADA) announced the winners of its Innovation Challenge competition. Innovators showcased novel ideas for diabetes care before a panel of potential funders and an audience of professionals in the field, with the goal of furthering transformative solutions for people living with diabetes, their families, and caregivers. Five finalists pitched ideas from the main stage at the ADA's 84th Scientific Sessions and three winners were chosen— Diatech Diabetes, Spotlight Communications, and Symbio Cell Tech.
ORLANDO, Fla., June 23, 2024 /PRNewswire/ -- Findings from three studies showcase new data on the latest developments in drug therapy innovations to treat obesity including new insights on GLP-1 (Glucagon-like peptide-1) receptor agonists. The data was presented as a late-breaking poster and oral presentations, respectively at the American Diabetes Association® (ADA) 84th Scientific Sessions in Orlando, FL.
Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions
INHALE-3 STUDY REVEALS POSITIVE READOUT IN HEAD-TO-HEAD COMPARISON OF INHALED INSULIN VS. USUAL CARE IN T1D; NEW DATA PRESENTED